BioMarin Pharmaceutical Inc. (BMRN)
$
52.32
-1.53 (-2.92%)
Key metrics
Financial statements
Free cash flow per share
3.6117
Market cap
10.4 Billion
Price to sales ratio
3.3945
Debt to equity
0.1002
Current ratio
5.5613
Income quality
0.9097
Average inventory
1.3 Billion
ROE
0.1148
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapies aimed at addressing serious and life-threatening rare diseases and medical conditions. The company’s portfolio includes Vimizim, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A; Naglazyme, a recombinant enzyme for treating MPS VI; and Kuvan, a synthetic oral treatment for phenylketonuria (PKU). Additionally, the product lineup features Palynziq, which is a PEGylated recombinant enzyme administered via subcutaneous injection to lower blood Phe levels; Brineura, designed for ceroid lipofuscinosis type 2; and Voxzogo, a daily injection aimed at treating achondroplasia. Another key product, Aldurazyme, is a purified protein mimicking the natural human enzyme alpha-L-iduronidase. BioMarin is also progressing with valoctocogene roxaparvovec in Phase III trials for severe hemophilia A, BMN 307 in Phase 1/2 trials for PKU, and BMN 255 in Phase 1/2 trials targeting primary hyperoxaluria. The total costs and expenses for the company are $2,369,701,000.00 reflecting its overall spending. The gross profit ratio is 0.80 indicating the efficiency of the company's production and sales operations. Furthermore, the company recorded a net income of $426,859,000.00 highlighting its profitability. Depreciation and amortization expenses of $96,426,000.00 are reported, reflecting the wear and tear of its assets, against a substantial revenue of $2,853,915,000.00 showcasing its strong market presence. As a publicly traded entity, BioMarin's stock is reasonably priced at $54.36 appealing to a broad range of investors. The stock maintains a high average trading volume of 2,121,784.00 indicating robust liquidity. With a mid-range market capitalization of $10,046,203,924.00 the company is recognized as a steady performer. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, BioMarin operates within the Healthcare sector, driving innovation and growth, which positions it favorably among its peers. This dynamic combination of product offerings and market strategies underscores BioMarin's commitment to enhancing the lives of patients facing rare diseases.
Is BioMarin Pharmaceutical Inc. (BMRN) a good investment?
Investing in BioMarin Pharmaceutical Inc. (BMRN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bullish outlook. Always conduct your own research before investing.
What is BioMarin Pharmaceutical Inc. (BMRN)'s stock forecast?
Analysts predict BioMarin Pharmaceutical Inc. stock to fluctuate between $51.79 (low) and $73.51 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is BioMarin Pharmaceutical Inc.'s market capitalization?
As of 2025-10-10, BioMarin Pharmaceutical Inc.'s market cap is $10,046,203,924, based on 192,014,601 outstanding shares.
How does BioMarin Pharmaceutical Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., BioMarin Pharmaceutical Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy BioMarin Pharmaceutical Inc. (BMRN) stock?
To buy BioMarin Pharmaceutical Inc. (BMRN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BMRN. Place an order (Market, Limit, etc.).
What is the best time to invest in BioMarin Pharmaceutical Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did BioMarin Pharmaceutical Inc. perform in the last earnings report?
Revenue: $2,853,915,000 | EPS: $2.25 | Growth: 152.81%.
Where can I find BioMarin Pharmaceutical Inc.'s investor relations reports?
Visit https://www.biomarin.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for BioMarin Pharmaceutical Inc.?
You can explore historical data from here
What is the all-time high and low for BioMarin Pharmaceutical Inc. stock?
All-time high: $117.77 (2023-01-27) | All-time low: $51.79 (2025-10-10).
What are the key trends affecting BioMarin Pharmaceutical Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
seekingalpha.com
BioMarin has both a solid revenue portfolio of several products and a promising pipeline. The market's main concern has been TransCon competition; however, the combination of Voxzogo and BMN 333 could effectively fight back. Even if the U.S. government were to regulate prices, it would only affect a small portion of the company, since 64% of its sales originate outside the US.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
seekingalpha.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to this good morning. Welcome to Morgan Stanley Global Healthcare Conference.
prnewswire.com
New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ BioMarin's planned submission to global health authorities on track for second half of 2025 SAN RAFAEL, Calif. , Sept. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data characterizing the efficacy and safety of PALYNZIQ ® (pegvaliase-pqpz) for the treatment of adolescents with phenylketonuria (PKU), which were presented at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, Sept.
seekingalpha.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:45 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst All right. Thank you very much for joining us today.
seekingalpha.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst Okay. Great. Hey, good morning, everyone.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
See all news
